A Research Guide for
Facing Ovarian Cancer

FDA-APPROVED The SOLO-1 trial demonstrated that olaparib maintenance therapy after first-line platinum-based chemotherapy in BRCA-mutated advanced ovarian cancer extended median progression-free survival from 13.8 months to 56 months — more than 4 years. At 7-year follow-up, 67% of olaparib patients had not required a subsequent line of therapy, suggesting the possibility of long-term disease control or even functional cure for some patients.

FDA-APPROVED The PRIMA trial showed that niraparib maintenance benefited patients with HRD-positive tumors regardless of BRCA mutation status. This expanded PARP inhibitor access beyond BRCA-mutated patients. However, the benefit in HRD-negative (biomarker-negative) patients was modest and is no longer a recommended indication.

FDA-APPROVED PAOLA-1 demonstrated that combining olaparib with bevacizumab as first-line maintenance in HRD-positive ovarian cancer significantly improved progression-free survival compared to bevacizumab alone (37.2 months vs. 17.7 months). This combination is a standard option for HRD-positive patients who received bevacizumab with their initial chemotherapy.

FDA-APPROVED Mirvetuximab soravtansine (Elahere) first received FDA accelerated approval in 2022 (SORAYA trial) and was converted to full approval in March 2024 for folate receptor alpha (FRa)-positive, platinum-resistant ovarian cancer. The confirmatory MIRASOL trial (NCT04209855) demonstrated improved overall survival compared to investigator’s choice chemotherapy (16.5 months vs. 12.7 months). This is the first antibody-drug conjugate approved for ovarian cancer and represents a meaningful new option for platinum-resistant disease.

FDA-APPROVED Relacorilant (Lifyorli) was FDA-approved on March 25, 2026, in combination with nab-paclitaxel (Abraxane) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. It is the first selective glucocorticoid receptor antagonist approved for cancer — it blocks cortisol signaling in tumor cells, which is thought to restore sensitivity to chemotherapy.

In the pivotal Phase 3 ROSELLA trial (NCT05257408; 381 patients), relacorilant plus nab-paclitaxel improved median progression-free survival (6.5 vs. 5.5 months) and median overall survival (16.0 vs. 11.9 months) compared with nab-paclitaxel alone. Unlike mirvetuximab, eligibility does not depend on folate receptor alpha status, so it is an option for patients regardless of FRa expression. Ask your gynecologic oncologist whether this combination is appropriate for you.

FDA-APPROVED Bevacizumab (Avastin), an anti-VEGF antibody, was the first targeted therapy approved for ovarian cancer. GOG-0218 and ICON7 showed that adding bevacizumab to frontline chemotherapy and continuing as maintenance improved progression-free survival, particularly in patients with advanced-stage disease and suboptimal cytoreduction. It is also approved for platinum-sensitive and platinum-resistant recurrence.

Ovarian cancer symptoms are often subtle and easily attributed to other causes. The most common symptoms are:

• Bloating (persistent, not intermittent)
• Pelvic or abdominal pain
• Difficulty eating or feeling full quickly
• Urinary urgency or frequency
• Fatigue, back pain, constipation, menstrual changes

Key point: If these symptoms are new, persistent (present most days for more than 2–3 weeks), and unusual for you, see your doctor. While these symptoms are common in many benign conditions, their persistence and combination should prompt evaluation.

• Pelvic examination: May reveal an adnexal mass (mass near the ovary or fallopian tube).
• Transvaginal ultrasound: The first imaging test. Evaluates the size, shape, and characteristics of ovarian masses (solid vs. cystic, presence of septations, blood flow).
• CA-125 blood test: Elevated in approximately 80% of advanced ovarian cancers. Less reliable in early-stage disease and premenopausal women (many benign conditions elevate CA-125). Useful for monitoring treatment response and recurrence.
• HE4 blood test: Another tumor marker that, combined with CA-125, can improve discrimination between malignant and benign pelvic masses (ROMA score).
• CT scan of chest, abdomen, and pelvis: Evaluates the extent of disease, presence of ascites, and whether the cancer has spread to lymph nodes, liver, lungs, or other sites. Essential for surgical planning.

The stretch between a worrying scan or blood test and a firm diagnosis can be one of the most anxious parts of the whole journey, partly because ovarian cancer is diagnosed differently from many other cancers. With most cancers a needle biopsy comes first; with ovarian cancer, the definitive diagnosis and the staging usually come from the surgery itself, because removing and examining the tissue is both how the diagnosis is confirmed and how the true extent of disease is determined. That means an ultrasound, a CA-125 level, and a CT scan can raise strong suspicion and guide planning, but they do not give a final answer on their own — and a single elevated CA-125 is not a diagnosis, since many benign conditions (fibroids, endometriosis, even menstruation) can raise it.

A few things help during this window. The most important is who you see: ask to be referred to a gynecologic oncologist before any surgery, because the specialist who first operates strongly influences how completely the cancer is removed and how accurately it is staged — and that, in turn, affects outcomes. It is reasonable to ask whether your team recommends surgery first or chemotherapy first (both are valid paths depending on how extensive the disease appears and how well you are), and to ask that genetic and tumor biomarker testing be set in motion early, since those results will shape your treatment. Bring someone with you to appointments, write your questions down, and know that a short, well-planned delay to get to the right surgeon is usually far more valuable than rushing to the first available operation.

BRCA1 and BRCA2 are tumor suppressor genes involved in DNA repair. Inherited (germline) mutations in these genes dramatically increase ovarian cancer risk:

• BRCA1 mutation carriers: 39–46% lifetime risk of ovarian cancer (vs. 1.2% in the general population)
• BRCA2 mutation carriers: 10–27% lifetime risk
• Approximately 15–20% of ovarian cancers have germline BRCA mutations
• Testing requires a blood or saliva sample sent to a genetic testing laboratory
• If you have a germline BRCA mutation, your blood relatives may also carry the mutation and should be offered genetic counseling and testing
• Prevention for unaffected relatives: because most high-grade serous ovarian cancers begin in the fallopian tube, risk-reducing removal of the tubes and ovaries (and, increasingly, opportunistic salpingectomy — removing the tubes at the time of other pelvic surgery) is offered to BRCA carriers and studied as a broader prevention strategy.

Why it matters for treatment: BRCA-mutated ovarian cancers respond exceptionally well to PARP inhibitors. SOLO-1 showed that maintenance olaparib in BRCA-mutated patients extended progression-free survival by more than 3 years.

Even if germline BRCA testing is negative, the tumor itself may have acquired BRCA mutations or other defects in homologous recombination repair (HRD):

• Somatic BRCA mutations: Found in an additional 5–7% of ovarian cancers. Same treatment implications as germline BRCA mutations, but not inherited.
• HRD testing (Myriad myChoice or similar): Measures genomic instability caused by defective DNA repair. An HRD-positive tumor may benefit from PARP inhibitors even without a BRCA mutation.
• HRD-positive/BRCA-negative patients: Benefit from niraparib maintenance (PRIMA) and olaparib+bevacizumab (PAOLA-1), though benefit is less dramatic than in BRCA-mutated patients.

• Folate receptor alpha (FRa): Expressed on approximately 80% of high-grade serous ovarian cancers. Required for eligibility for mirvetuximab soravtansine (Elahere). Tested by immunohistochemistry (IHC) on tumor tissue.
• Mismatch repair (MMR) / microsatellite instability (MSI): Found in approximately 2–4% of ovarian cancers. MMR-deficient/MSI-high tumors may respond to immune checkpoint inhibitors (pembrolizumab, dostarlimab). A dMMR/MSI-high result can also be a clue to Lynch syndrome, an inherited condition that raises the risk of ovarian, endometrial, colorectal, and other cancers — so it should prompt referral for genetic counseling and testing of relatives.
• PD-L1 expression: Currently has limited clinical utility in ovarian cancer outside of dMMR/MSI-H tumors.

It is worth understanding why your team pushes for genetic and biomarker testing right away, because the timing genuinely matters. The decision about maintenance therapy — the treatment given after chemotherapy to keep the cancer from coming back — is made at the end of your first chemotherapy, and the best maintenance choice depends on your BRCA and HRD results. If those results are not back in time, a valuable option can be missed. That is why testing should start at diagnosis, why your surgeon will often bank tumor tissue at your first operation (HRD testing needs good-quality tissue), and why a delay in testing is not a harmless administrative gap — it can narrow your choices. Practically: ask early whether germline (blood/saliva) BRCA testing has been ordered, and whether your tumor will be tested for somatic BRCA, HRD, FRα, and MMR/MSI.

The other reason this testing matters reaches beyond you. An inherited (germline) BRCA mutation does not only explain your cancer — it means close blood relatives may carry the same mutation and face increased risks of ovarian, breast, and other cancers. A positive result opens the door to cascade testing: relatives can be offered counseling and testing, and those who carry the mutation can take real preventive steps, including risk-reducing removal of the tubes and ovaries, which can prevent ovarian cancer before it ever starts. A dMMR/MSI-high result can similarly point to Lynch syndrome, another inherited condition worth identifying in a family. In other words, your testing can become a gift of foresight to the people you love — one of the few silver linings in a hard diagnosis. Genetic counseling helps you and your family understand and act on these results.

• What type and stage of ovarian cancer do I have?
• Have I been referred for germline BRCA testing?
• Has my tumor been tested for somatic BRCA mutations and HRD?
• Has FRa expression been tested on my tumor tissue?
• Should my family members be tested for inherited cancer risk?
• Am I a candidate for primary surgery or neoadjuvant chemotherapy?
• Will I be eligible for PARP inhibitor maintenance based on my biomarkers?
• Is there a clinical trial available for my situation?

Primary debulking surgery is performed upfront before chemotherapy when the surgeon believes complete or optimal cytoreduction is achievable. Standard components include:

• Total abdominal hysterectomy (removal of the uterus)
• Bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes)
• Omentectomy (removal of the omentum, a fatty tissue layer that often harbors cancer deposits)
• Lymph node sampling or systematic lymphadenectomy
• Peritoneal biopsies from multiple sites
• Resection of any other involved tissues (bowel, diaphragm, spleen, etc.) as needed for complete tumor removal

The goal is no visible residual disease. Multiple studies confirm that patients with no visible residual disease after surgery have the best survival outcomes.

When the disease is too extensive for safe upfront complete cytoreduction, or when the patient is not medically fit for major surgery initially, neoadjuvant chemotherapy is given first (typically 3–4 cycles), followed by interval debulking surgery, then more chemotherapy afterward.

• CHORUS and EORTC 55971 trials showed that NACT+IDS produced similar survival to PDS in patients with very bulky disease
• NACT+IDS may have fewer surgical complications and shorter hospital stays
• The optimal approach (PDS vs. NACT+IDS) should be determined by a gynecologic oncologist based on disease extent, resectability, and patient fitness

For select young patients with early-stage disease (stage IA, low-grade or grade 1), fertility-sparing surgery may be considered, preserving the uterus and contralateral ovary. This requires careful surgical staging and is only appropriate for specific histologic subtypes. Discuss this with a gynecologic oncologist experienced in fertility preservation before surgery.

Cytoreductive (debulking) surgery for ovarian cancer is a major operation, and knowing roughly what it involves can make it less frightening. Because the goal is to remove all visible cancer, the surgery is often more extensive than the name “ovarian” suggests: along with the ovaries, tubes, uterus, and omentum, the surgeon may need to remove or strip cancer deposits from the surfaces of the bowel, diaphragm, or other abdominal organs, and occasionally remove a short segment of bowel. This is why the operation is best done by a specialized gynecologic-oncology surgical team — the thoroughness of that first surgery is one of the strongest predictors of how well treatment works. You will typically be in the hospital for several days, and full recovery at home usually takes several weeks, with fatigue often lingering longer than the incision discomfort.

A few practical realities help with planning. Most women will go through menopause immediately if they had not already, because both ovaries are removed — ask your team about managing menopausal symptoms. Chemotherapy usually begins a few weeks after surgery, once you have healed enough, so recovery and the next phase of treatment are paced together. Arrange help at home for the first couple of weeks (lifting and driving are restricted), expect your energy to return gradually rather than all at once, and report fevers, worsening pain, or wound problems promptly. If your disease is very extensive or you are not well enough for major surgery upfront, your team may recommend chemotherapy first to shrink the cancer and make a safer, more complete operation possible later — this is a legitimate, evidence-based path, not a sign of giving up.

The standard first-line chemotherapy for epithelial ovarian cancer is:

• Carboplatin (AUC 5–6) + Paclitaxel (175 mg/m²) every 3 weeks for 6 cycles
• Alternative: Dose-dense weekly paclitaxel (80 mg/m² weekly) with every-3-week carboplatin — may improve outcomes in some populations (Japanese JGOG 3016 trial)
• Response rate in newly diagnosed advanced disease: approximately 70–80%
• Common side effects: nausea, fatigue, hair loss, low blood counts, neuropathy (tingling/numbness in hands and feet from paclitaxel)

HIPEC involves bathing the abdominal cavity in heated chemotherapy (typically cisplatin) during surgery. The OVHIPEC-1 trial showed improved overall survival when HIPEC was added to interval debulking surgery after neoadjuvant chemotherapy (45.7 months vs. 33.9 months). However, this remains somewhat controversial, and the OVHIPEC-2 confirmatory trial results are awaited. HIPEC should only be performed at experienced centers.

IP chemotherapy delivers drugs directly into the abdominal cavity, where ovarian cancer is concentrated. GOG-172 showed that IP cisplatin + IV paclitaxel improved overall survival compared to IV-only chemotherapy in optimally debulked stage III patients. However, IP chemotherapy is more toxic, requires an abdominal port, and has been less widely adopted. Modified IP/IV regimens and HIPEC represent newer approaches to peritoneal drug delivery.

For most women, first-line chemotherapy means six cycles of carboplatin and paclitaxel given roughly every three weeks — so the whole course usually spans about four to five months. Each treatment is an outpatient infusion: you sit in a comfortable chair for a few hours while the drugs are given through a vein or an implanted port, often with pre-medications to prevent nausea and allergic reactions. Many people find the anticipation worse than the reality of infusion day itself. A typical rhythm emerges — the first few days after a cycle tend to be the hardest (fatigue, some nausea, low appetite), the middle stretch is usually better, and then it is time for the next cycle. Anti-nausea medicines today are genuinely effective, so uncontrolled vomiting should not be accepted as inevitable — tell your team if you are struggling and they will adjust.

The side effects worth knowing about are manageable but real: hair loss (usually starting after the first cycle or two, and it grows back after treatment), fatigue that tends to accumulate over the cycles, lowered blood counts (your team checks blood before each cycle and watches for infection risk), and the tingling or numbness in fingers and toes called neuropathy that comes from paclitaxel. Report neuropathy early — catching it before it becomes severe lets your team adjust the dose and prevent lasting nerve damage. Beyond that, simple things help: stay hydrated, accept help, rest without guilt, watch for fever (a temperature of 100.4°F/38°C or higher is an urgent call to your team), and keep moving gently when you can. Most women continue much of daily life through chemotherapy, with good days and harder days, and come out the other side — and the maintenance therapy that often follows is generally much easier than the chemotherapy itself.

FDA-APPROVED SOLO-1 trial (NCT01844986):

• Population: Newly diagnosed BRCA-mutated advanced ovarian cancer in complete or partial response after first-line platinum chemotherapy
• Results: Median PFS 56.0 months with olaparib vs. 13.8 months with placebo
• 7-year follow-up: 67% of olaparib patients had not required subsequent therapy
• Dosing: Olaparib 300 mg PO twice daily for up to 2 years
• Common side effects: Nausea, fatigue, anemia. Serious but rare risks include myelodysplastic syndrome (MDS) and acute myeloid leukemia (<2%)

FDA-APPROVED PRIMA/ENGOT-OV26 trial (NCT02655016):

• Population: Newly diagnosed advanced ovarian cancer in response after first-line platinum chemotherapy (regardless of BRCA status but benefit stratified by HRD)
• HRD-positive group: Median PFS 21.9 months with niraparib vs. 10.4 months with placebo
• Overall population: Modest PFS benefit but less convincing in HRD-negative patients
• Dosing: Niraparib 200 or 300 mg PO daily (individualized by body weight and platelet count) for up to 3 years
• Common side effects: Thrombocytopenia (low platelets — more common than with olaparib), anemia, nausea, fatigue, hypertension

Important update: Following analysis of overall survival data, the indication for niraparib maintenance has been refined to focus on HRD-positive and/or BRCA-mutated patients. Maintenance in biomarker-negative (HRD-negative) patients is no longer recommended.

FDA-APPROVED PAOLA-1 trial (NCT02477644):

• Population: Newly diagnosed advanced ovarian cancer who received first-line platinum + bevacizumab and achieved response
• HRD-positive group: Median PFS 37.2 months with olaparib + bevacizumab vs. 17.7 months with bevacizumab alone
• HRD-negative group: No significant benefit from adding olaparib to bevacizumab
• Key point: This combination is appropriate only if bevacizumab was already part of the first-line regimen AND the tumor is HRD-positive

Maintenance therapy is a different experience from chemotherapy, and it helps to know what to expect because this is the phase doing much of the quiet work of keeping the cancer from coming back. A PARP inhibitor is a pill you take at home — olaparib twice daily, niraparib once daily — not an infusion, so there are no chemo chairs and no needles for the drug itself. You continue it for a set period (up to two years for olaparib in the first-line BRCA setting, up to three for niraparib) or until the cancer shows signs of returning. The side effects are generally milder than chemotherapy and tend to be worst in the first weeks, then settle: fatigue, nausea (often helped by taking the pill with food and by timing the dose), and lowered blood counts are the common ones. Niraparib is more likely to drop platelets and raise blood pressure, especially early, while olaparib more often causes anemia — which is why you will have frequent blood tests at the start (weekly for the first month or so on niraparib) and why your team may adjust the dose. Dose reduction is normal and does not mean the drug is failing; it is how the treatment is tailored to you.

Two things are worth naming. First, there is a small (roughly 1–2%) long-term risk of serious bone-marrow disorders (MDS/AML) with prolonged PARP use, which is why blood counts are monitored even once you feel well — for most patients the benefit in delaying recurrence clearly outweighs this rare risk, but it is a real reason to keep your monitoring appointments. Second, the shift from active chemotherapy into maintenance, and the periodic scans that come with it, can stir real anxiety — the so-called “scanxiety” many describe. That feeling is normal; lean on your team, ask what your CA-125 trend and scans actually mean, and remember that being on maintenance is itself a sign that your treatment is working and being actively protected.

• GOG-0218 trial (NCT00262847): Bevacizumab added to carboplatin/paclitaxel and continued as maintenance improved PFS (14.1 vs. 10.3 months) in stage III/IV ovarian cancer
• ICON7: Confirmed PFS benefit, with greatest benefit in high-risk subgroup (stage IV or stage III with >1 cm residual disease after surgery)
• Dosing: Bevacizumab 15 mg/kg IV every 3 weeks during chemotherapy and as maintenance for up to 15 months total
• Key side effects: Hypertension, proteinuria, delayed wound healing (must wait at least 28 days after major surgery before starting), rare but serious risks include GI perforation and thromboembolic events

• Will I have primary surgery or neoadjuvant chemotherapy first?
• What is the goal of surgery — complete cytoreduction?
• Am I a candidate for PARP inhibitor maintenance?
• Should bevacizumab be part of my treatment plan?
• What are the expected side effects of my chemotherapy regimen?
• How will my BRCA/HRD status affect my maintenance therapy options?
• How long will maintenance therapy last?
• What monitoring will I need during treatment?
• Is HIPEC an option for me, and does your center perform it?
• Are there clinical trials I should consider?

Approximately 2–4% of ovarian cancers have mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). These tumors may respond to immune checkpoint inhibitors:

• Pembrolizumab (Keytruda): FDA-approved for any dMMR/MSI-H solid tumor, including ovarian cancer
• Dostarlimab (Jemperli): FDA-approved for dMMR recurrent solid tumors

Response rates in dMMR/MSI-H ovarian cancer are approximately 30–40%, and some responses are durable. All ovarian cancer patients should have MMR/MSI testing performed on their tumor.

FDA-APPROVED Mirvetuximab soravtansine is an antibody-drug conjugate targeting folate receptor alpha (FRa). It delivers a potent cell-killing payload directly to FRa-expressing cancer cells.

• Indication: FRa-positive, platinum-resistant ovarian cancer that has received 1–3 prior lines of therapy
• MIRASOL trial (NCT04209855): Improved overall survival (16.5 vs. 12.7 months) and PFS (5.6 vs. 4.0 months) vs. investigator’s choice chemotherapy
• Requires FRa testing: Must have high FRa expression on IHC before treatment
• Key side effects: Ocular toxicity (blurred vision, keratopathy — requires regular eye exams), nausea, fatigue, peripheral neuropathy

The most distinctive thing about mirvetuximab soravtansine (Elahere) is its effect on the eyes, and understanding it ahead of time makes it far less alarming. Because the target the drug homes in on (folate receptor alpha) is also present on the surface of the cornea, a substantial number of patients develop eye-related effects — most often blurred vision, dry or gritty eyes, and changes to the corneal surface (keratopathy). The reassuring news is that these are usually reversible, are managed with a well-established routine, and rarely force patients to stop the drug when that routine is followed.

What that routine looks like in practice: you will have an eye exam before starting and before each cycle, so changes are caught early; you will use lubricating (preservative-free) artificial tears regularly throughout the day and, per your team's protocol, prescription steroid eye drops around each dose; and you will be asked to avoid contact lenses during treatment. Practical adjustments — not driving when your vision is blurry, good lighting, and giving the drops time to work — make a real difference day to day. Report any new vision change promptly rather than waiting, because early dose holds or reductions usually let your eyes recover and keep you on an effective therapy. It is also worth knowing that Elahere's label carries less common warnings beyond the eyes — lung inflammation (pneumonitis) and nerve symptoms (neuropathy) — so mention any new shortness of breath, cough, or tingling at your visits. With the monitoring and drop routine in place, most patients tolerate this drug well and benefit from an option that, in the MIRASOL trial, helped FRα-positive patients live longer.

• Bone-marrow suppression — low red cells, white cells, and platelets are common. You will have regular blood counts (CBC); dose interruptions or reductions are routine and expected.
• Myelodysplastic syndrome / acute myeloid leukemia (MDS/AML) — a rare but serious blood cancer risk listed in the labels of all PARP inhibitors. If blood counts stay low after a treatment break, your doctor will investigate the bone marrow.
• Pneumonitis (lung inflammation) — report new cough, shortness of breath, or fever. Rare but can be severe.
• Niraparib specifically: high blood pressure and cardiovascular effects (BP is monitored weekly for the first 2 months, then monthly through the first year), and rarely PRES (a reversible brain condition causing headache, confusion, or seizures — seek care urgently).
• Olaparib specifically: venous blood clots and liver enzyme elevations.
• Nausea and fatigue are common early and usually improve; anti-nausea medicine helps.

• Gastrointestinal perforation and fistula — a serious, sometimes life-threatening hole or abnormal connection in the bowel. Sudden severe abdominal pain is a medical emergency.
• Bleeding and blood clots — both arterial (stroke, heart attack) and venous (leg/lung clots) events occur more often with bevacizumab.
• High blood pressure and protein in the urine (kidney effects) — both are monitored at each visit.
• Impaired wound healing — bevacizumab is stopped for several weeks before and after surgery.
• Rarely PRES, congestive heart failure, and ovarian failure (see the Pregnancy & Fertility section).

• Myelosuppression (low blood counts), peripheral neuropathy (numbness/tingling in hands and feet from paclitaxel), nausea, and hair loss are the most common chemotherapy effects.
• Carboplatin hypersensitivity — allergic reactions become more likely after multiple cycles (typically the 6th onward). Tell your nurse immediately about flushing, itching, or trouble breathing during an infusion.
• Relacorilant (Lifyorli) is taken as a pill the day before, day of, and day after each nab-paclitaxel (Abraxane) infusion. Because it blocks cortisol signaling, your team monitors for related effects; the nab-paclitaxel partner drug adds neutropenia and neuropathy risk.

Alongside the drug-specific warnings above, a large part of living well through ovarian cancer treatment is managing the everyday symptoms — and there is a great deal that can be done. Nausea is far more controllable than it used to be; modern anti-sickness medicines work well, so if you are still queasy, your team can adjust the combination rather than have you tough it out. Fatigue is the most common and most underestimated symptom; gentle activity (even short walks) paradoxically helps, as does pacing your day, prioritizing what matters, and letting your team check for treatable contributors like anemia or thyroid changes. Appetite and nutrition often suffer from taste changes, early fullness, and bloating; small frequent meals, protein-rich foods, and a referral to an oncology dietitian make a real difference — you do not need a special “cancer diet,” just enough nourishment to get through treatment.

Two issues specific to ovarian cancer deserve mention. Ascites — fluid building up in the abdomen — can cause bloating, breathlessness, and discomfort; when it does, a simple drainage procedure (paracentesis) can bring quick relief, and treating the cancer itself usually reduces the fluid over time. Bowel symptoms are common, whether constipation (often from anti-nausea or pain medicines) or, less often, signs of partial blockage from disease — report a change in bowel habits, and ask about a bowel regimen if you are on opioids or ondansetron. Finally, do not overlook palliative care: these specialist teams focus on symptoms, comfort, and quality of life alongside active cancer treatment, at any stage — they are not the same as hospice, and involving them early is associated with feeling better and sometimes living longer. Asking for help with symptoms is not a distraction from fighting the cancer; it is part of fighting it well.

• Fertility-sparing surgery — for selected early-stage or germ-cell/borderline tumors, a surgeon may be able to remove the affected ovary while preserving the uterus and the other ovary, leaving open the possibility of a future pregnancy. This must be discussed and planned before the operation.
• Egg, embryo, or ovarian-tissue freezing — ask for a referral to a reproductive endocrinologist before chemotherapy starts, as treatment can damage egg supply.
• Ovarian failure from bevacizumab — the Avastin label specifically lists ovarian failure (loss of ovarian function); recovery after stopping is not guaranteed. Raise this if future fertility matters to you.

• During pregnancy — ovarian cancer in pregnancy is managed by a multidisciplinary team (gynecologic oncology plus maternal-fetal medicine). Some surgery and chemotherapy can be given in the second and third trimesters; the plan is individualized to protect both patient and baby.
• Breastfeeding — is not recommended during treatment with these therapies, and for a period afterward, because the drugs can pass to the infant. Ask your team how long to wait.

If the cancer returns more than 6 months after completing platinum-based chemotherapy, it is considered platinum-sensitive. These patients can be re-treated with platinum-based combinations:

• Carboplatin + paclitaxel (standard)
• Carboplatin + gemcitabine (especially with bevacizumab — OCEANS trial)
• Carboplatin + pegylated liposomal doxorubicin (PLD)
• PARP inhibitor maintenance after response: Olaparib (SOLO-2, BRCA-mutated) and niraparib (NOVA, regardless of BRCA but focus on HRD-positive) have both shown PFS benefit in the recurrent setting after platinum response

If the cancer returns within 6 months of platinum chemotherapy, it is considered platinum-resistant. This is more challenging to treat. Options include:

• Mirvetuximab soravtansine (Elahere): If FRa-positive (approximately 40% of platinum-resistant patients have high FRa). MIRASOL showed survival benefit.
• Relacorilant (Lifyorli) + nab-paclitaxel: FDA-approved March 2026 after prior bevacizumab. The ROSELLA trial showed improved overall survival (16.0 vs. 11.9 months). Does not require FRa testing.
• Pegylated liposomal doxorubicin (Doxil): Given every 4 weeks. Response rate approximately 15–20%.
• Weekly paclitaxel ± bevacizumab: AURELIA trial showed that adding bevacizumab to weekly paclitaxel improved PFS in platinum-resistant disease.
• Topotecan: Given IV or orally. Response rate approximately 10–15%.
• Gemcitabine: Can be used as single agent.
• Bevacizumab + chemotherapy: FDA-approved for platinum-resistant recurrence in combination with paclitaxel, PLD, or topotecan.

Clinical trials are especially important for platinum-resistant disease, as current treatment options have limited efficacy. New ADCs, bispecific antibodies, and combination strategies are under investigation.

In select patients with platinum-sensitive recurrence and limited disease on imaging, secondary cytoreductive surgery may be considered. The DESKTOP III trial showed an overall survival benefit for secondary surgery in patients meeting the AGO score criteria (complete resection at primary surgery, good performance status, no ascites). This should only be performed at experienced centers by gynecologic oncologists.

Learning that ovarian cancer has returned is one of the hardest moments, and it is easy to hear it as failure or as the end of options. It is neither. Recurrence is, unfortunately, common in advanced ovarian cancer — the majority of patients experience it — which is precisely why the treatment landscape has been built around it, with a deep bench of effective therapies for the recurrent setting. Many women live for years after a first recurrence, moving through successive treatments with periods of stability and good quality of life in between. Increasingly, advanced ovarian cancer is managed less like a single battle to be won or lost and more like a chronic condition to be controlled over time — treated, watched, and treated again as needed.

A few things make this phase more navigable. The single most important question is whether your recurrence is platinum-sensitive (returning more than six months after platinum), because that opens the door to platinum re-treatment and often another round of PARP maintenance — a genuinely favorable situation. Ask whether your tumor should be re-biopsied and re-tested, since biomarkers like FRα can guide newer options (such as Elahere) that may not have applied before, and since the cancer can change over time. Clinical trials become especially valuable now, particularly for platinum-resistant disease, and are worth raising early rather than as a last resort. It is also fair and wise to ask directly about the goal of the next treatment — long-term control, shrinking the cancer, or easing symptoms — so your choices reflect what matters most to you. Finally, recurrence takes an emotional toll that deserves real support: counseling, support groups, and palliative-care teams (which help with symptoms and quality of life alongside active treatment, at any stage) are signs of good care, not surrender.

• Is my recurrence considered platinum-sensitive or platinum-resistant?
• Should my tumor be re-biopsied and tested for new biomarkers?
• Am I eligible for PARP inhibitor maintenance after recurrence treatment?
• Has FRa expression been tested on my tumor?
• Is secondary debulking surgery an option for me?
• What clinical trials are available for my situation?
• Should I consider bevacizumab with my recurrence treatment?
• What are the goals of treatment at this point — cure, long-term control, or symptom management?

BRCA and HRD testing rates vary significantly internationally. In high-income countries, germline BRCA testing is increasingly standard. However:

• In some low- and middle-income countries, BRCA testing may not be routinely available or affordable
• HRD testing (Myriad myChoice or equivalent) requires tumor tissue and is not universally available
• Without BRCA/HRD testing, patients cannot access PARP inhibitor maintenance, which represents the most significant treatment advance in ovarian cancer
• Advocacy organizations (OCRA, ESGO) are working to improve testing access globally

If you are treated outside the United States, or you are comparing notes with people in other countries, it helps to know what actually varies — and what doesn't. The reassuring part is that the backbone of ovarian cancer care is genuinely global: surgery by a gynecologic oncologist, platinum-based chemotherapy, and the major PARP inhibitors (olaparib, niraparib) are approved and broadly available across the US, Europe, the UK, Canada, Australia, Japan, and beyond. What differs is mostly the newest agents and the fine print of access. Some recent therapies are available in one region before another — mirvetuximab (Elahere), for example, has been available in the US while its European review is still in progress — and reimbursement (what a health system or insurer will actually pay for) varies considerably, so a drug being “approved” in a country does not always mean it is funded for every patient.

The most important international difference, though, is one many people overlook: access to biomarker testing. Because BRCA and HRD results are the gateway to PARP inhibitor maintenance — the single biggest advance in the disease — a patient who cannot get tested effectively cannot access that treatment, and testing availability is far from universal, especially in lower-resource settings. The practical takeaways are simple wherever you live: make sure germline BRCA testing (and, where possible, tumor HRD and FRα testing) is actually done, ask specifically what your health system covers for maintenance and recurrence, and lean on advocacy organizations — which often help with navigation, testing access, and clinical-trial options that cross borders. If a therapy you have read about is not available where you are, ask your team whether an equivalent option, a clinical trial, or a compassionate-access route exists.

WITHDRAWN Rucaparib (Rubraca) was previously approved as maintenance therapy for recurrent ovarian cancer regardless of BRCA status based on PFS data from ARIEL3. However, overall survival analysis did not show a benefit in non-BRCA patients. In 2022, the manufacturer voluntarily withdrew the non-BRCA maintenance indication (and, separately that same year, withdrew an older late-line treatment use after the ARIEL4 trial showed worse survival). Rucaparib remains available only for BRCA-mutated recurrent ovarian cancer.

WITHDRAWN Olaparib (Lynparza) once had a treatment (not maintenance) indication for BRCA-mutated ovarian cancer after three or more prior chemotherapies (based on Study 42). After the confirmatory SOLO3 trial raised overall-survival concerns, this late-line treatment indication was voluntarily withdrawn in August 2022. Olaparib remains a cornerstone of maintenance therapy (SOLO-1 first-line in BRCA-mutated disease; PAOLA-1 with bevacizumab in HRD-positive disease).

NOT RECOMMENDED Initial approvals of niraparib (PRIMA) and rucaparib (ARIEL3) included all-comer populations regardless of biomarker status. However, subsequent overall survival analyses consistently showed that patients without BRCA mutations or HRD did not benefit meaningfully from PARP inhibitor maintenance. Current guidelines recommend PARP inhibitors only for BRCA-mutated or HRD-positive patients in the first-line setting.

FAILED Multiple trials of PD-1/PD-L1 inhibitor monotherapy (nivolumab, pembrolizumab, avelumab) in unselected ovarian cancer populations showed response rates of only 5–15% with limited durability. The exception is dMMR/MSI-H tumors (~2–4% of ovarian cancers), which do respond. JAVELIN Ovarian 200 (avelumab maintenance) did not improve PFS or OS. IMagyn050 (atezolizumab + chemo + bev) did not meet its primary endpoint.

INCONCLUSIVE While earlier studies (GOG-172) showed a benefit for IP chemotherapy, the subsequent GOG-252 trial, which compared IP chemotherapy with IV chemotherapy (both with bevacizumab), showed no difference in PFS. The addition of bevacizumab to both arms may have diminished the IP advantage. IP chemotherapy has been largely supplanted by HIPEC and PARP inhibitor maintenance approaches.

• Is secondary surgery an option based on the DESKTOP criteria?
• Should my tumor be re-biopsied for updated biomarker testing?
• Am I eligible for mirvetuximab soravtansine (Elahere)?
• What is the current evidence for immunotherapy in my case?
• Are there clinical trials available for my situation?
• What are the goals of treatment at this stage?
• What palliative care and supportive services are available?
• Should I continue aggressive treatment, and what are the tradeoffs?

A list of withdrawn and failed treatments can look discouraging, but reading it the right way is genuinely protective — and it reveals the single most important principle in modern ovarian cancer care. Notice the pattern across these entries: PARP inhibitors were pulled back for patients without a BRCA mutation or HRD, and immunotherapy given on its own failed in unselected patients. In other words, these were not bad drugs — they were good drugs given to the wrong patients. The same olaparib that lost its late-line treatment role remains a cornerstone of maintenance for the patients it truly helps; the same checkpoint inhibitors that failed broadly do work in the small group with dMMR/MSI-high tumors. The lesson is that matching the treatment to your specific tumor biology is everything, which is exactly why your biomarker results (BRCA, HRD, FRα, MMR/MSI) matter so much.

For you as a patient, this knowledge does two things. It protects you from spending precious time, money, and side-effect tolerance on a treatment that the evidence says is unlikely to help your cancer — and it gives you a fair question to ask whenever a therapy is proposed: “What in my tumor's biology suggests this will work for me?” It is also a reason for cautious optimism about hopeful-sounding headlines: a drug that helped in a trial may not apply to your subtype or biomarker profile, and a good oncologist will tell you honestly whether it does. Far from being a catalogue of dead ends, the record of what didn't work is a map showing how ovarian cancer care became more precise — and how that precision now works in your favor.

• Understand the treatment plan. Know what drugs are being given, the expected side effects, and the schedule of cycles. Keep a treatment calendar.
• Manage side effects. Nausea, fatigue, and neuropathy are common with platinum-based chemotherapy. Anti-nausea medications should be taken as prescribed. Report new or worsening symptoms to the oncology team.
• Track CA-125 levels. While not every oncologist recommends patients track this number closely (it can cause anxiety), understanding the trend can help you participate in care decisions.
• Nutrition matters. Appetite loss, taste changes, and ascites-related bloating are common. Small, frequent meals. Consider a consultation with an oncology dietitian.

• PARP inhibitor maintenance is typically well-tolerated but requires regular blood count monitoring. The most common side effects are fatigue, nausea, and anemia.
• Duration is significant: PARP inhibitor maintenance lasts up to 2–3 years. This is a long commitment. Help the patient maintain routines and normalcy.
• Report unusual symptoms: While rare, PARP inhibitors carry a small risk of myelodysplastic syndrome (MDS). Report persistent fatigue, easy bruising, or frequent infections.

• Ovarian cancer’s high recurrence rate creates ongoing anxiety. Many patients describe “scanxiety” — anxiety around scheduled imaging and CA-125 checks. This is normal and should be discussed openly.
• Connect with support communities. The Ovarian Cancer Research Alliance (OCRA) at ocrahope.org offers peer support, and the National Ovarian Cancer Coalition provides resources. Online communities on Inspire and Smart Patients connect patients and caregivers.
• Palliative care is not the same as hospice. Palliative care teams can help manage symptoms, pain, and quality of life alongside active treatment. Consider a palliative care consultation early in the treatment process.
• Caregiver burnout is real. Take care of yourself. Accept help. Use respite care when available. Your health matters too.

Beyond the medical side, caregiving for ovarian cancer is a logistics job that can quietly become overwhelming, and a little structure goes a long way. A few systems help: keep one place — a notebook or a shared phone app — for the treatment calendar, the current medication list (including doses and the contraception/monitoring schedule), questions for the next visit, and key phone numbers. Bring it to every appointment and, when you can, bring a second set of ears, because it is genuinely hard for the patient to absorb everything that is said. Coordinating rides to and from infusions (patients often cannot drive after certain treatments), batching pharmacy runs, and setting up a simple way for friends to help — a meal schedule, an errands list — removes daily friction. Do not overlook the financial and insurance side: ask the cancer center for a social worker or financial navigator early, as ovarian cancer treatment is long and the costs (and paperwork) accumulate; organizations like the American Cancer Society and disease-specific foundations offer help with transportation, lodging, and copay assistance.

The harder truth is that caregivers carry their own grief, fear, and exhaustion, often while trying to stay strong for someone else — and running yourself empty helps no one. Protecting yourself is part of the job, not a distraction from it: accept offers of help instead of absorbing everything alone, share the load among family and friends rather than designating a single hero, use respite care when it is available, and keep some thread of your own life, sleep, and support intact. Your own feelings deserve attention too, and counseling or a caregiver support group can be a lifeline. Caring for someone through ovarian cancer is a marathon measured in months and years; pacing yourself, and letting yourself be supported in turn, is what makes it sustainable.

• “ovarian cancer olaparib SOLO-1 maintenance”
• “niraparib PRIMA ENGOT-OV26 ovarian”
• “olaparib bevacizumab PAOLA-1”
• “mirvetuximab soravtansine MIRASOL platinum-resistant”
• “bevacizumab GOG-0218 ovarian cancer”
• “HIPEC ovarian cancer OVHIPEC”
• “BRCA HRD PARP inhibitor ovarian”
• “platinum-resistant ovarian cancer treatment”

• “antibody-drug conjugate ovarian cancer”
• “immunotherapy ovarian cancer dMMR MSI-H”
• “durvalumab olaparib DUO-O ovarian”
• “folate receptor alpha targeted therapy ovarian”
• “PARP inhibitor resistance ovarian cancer”
• “low-grade serous ovarian cancer MEK inhibitor”